Federal News
BARDA Awards Evotec Biologics Contract
March 24, 2026
Just – Evotec Biologics, a subsidiary of Evotec SE, has secured a U.S. government contract from the Biomedical Advanced Research and Development Authority (BARDA) valued up to $10 million. The contract focuses on developing scalable manufacturing processes for a monoclonal antibody cocktail targeting filoviruses, including Ebola and Sudan viruses. This award underscores BARDA's continued investment in advanced biologics manufacturing capabilities to address high-consequence infectious diseases and highlights Evotec's biologics division as a key growth driver amid its corporate restructuring.
- Why this matters: BARDA's contract signals ongoing federal prioritization of scalable biologics manufacturing for emerging infectious diseases, creating opportunities for specialized biopharmaceutical contractors.
- The contract's focus on monoclonal antibody treatments aligns with increasing demand for rapid-response therapeutics against viral threats.
- Procurement professionals should note the strategic importance of BARDA as a funding source for biologics process development and consider partnerships or capabilities in scalable manufacturing.
- Companies in biologics manufacturing can leverage this development to position themselves for future BARDA or BioMaP consortium opportunities targeting infectious disease countermeasures.
The biologics business is regarded as one of the most stable drivers of future growth.
— Evotec SE management
Agencies
Biomedical Advanced Research and Development Authority, BioMaP consortium
Vendors
Just – Evotec Biologics, Evotec SE
Contracts
up to $10 million
Locations
Sources
- Evotec's Biologics Division Secures Key U.S. Government Contract · AD HOC NEWS · Mar 24